S-1 is an active anticancer agent for advanced thymic carcinoma

Lung Cancer

Volumn 70, Issue 3, 2010, Pages 357-363

  Okuma, Yusuke ^a   Shimokawa, Tsuneo ^a,b   Takagi, Yusuke ^a   Hosomi, Yukio ^a   Iguchi, Mari ^a   Okamura, Tatsuru ^a   Shibuya, Masahiko ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

Author keywords

Metastasis; S 1; Salvage chemotherapy; Squamous cell carcinoma; Thymic carcinoma

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMRUBICIN; CARBOPLATIN; CISPLATIN; GEMCITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; SALVAGE THERAPY; THYMUS CANCER; THYMUS CARCINOMA; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OXONIC ACID; SALVAGE THERAPY; TEGAFUR; THYMUS NEOPLASMS;

EID: 78049355384     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.09.004     Document Type: Article

References (35)

1. Shimosato Y., Kameya T., Nagai K., Suemasu K. Squamous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol 1977, 1:109-121.
2. Travis W.D., Brambilla E., Müller-Hermelink H.K., Harris C.C. World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura thymus and heart 2004, IARC press, Lyon, Chapter 3.
3. Yano M., Sasaki H., Yokoyama T., Yukiue H., Kawano O., Suzuki S., et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008, 3:265-269.
4. Eng T.Y., Fuller C.D., Jagirdar J., Bains Y., Thomas C.R. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004, 59:654-664.
5. Peters G.J., Noordhuis P., Van Kuilenburg A.B., Schornagel J.H., Gall H., Turner S.L., et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol 2003, 52:1-12.
6. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001, 85:939-943.
7. Totani Y., Saito Y., Hayashi M., Tada T., Kohashi Y., Mieno Y., et al. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009, 64:1181-1185.
8. Carlson R.W., Dorfman R.F., Sikic B.I. Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Cancer 1990, 66:2092-2094.
9. Koizumi T., Takabayashi Y., Yamagishi S., Tsushima K., Takamizawa A., Tsukadaira A., et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002, 25:266-268.
10. Kitami A., Suzuki T., Kamio Y., Suzuki S. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J Clin Oncol 2001, 31:601-604.
11. Yoh K., Goto K., Ishii G., Niho S., Ohmatsu H., Kubota K., et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003, 98:926-931.
12. Loehrer P.J., Jiroutek M., Aisner S., Aisner J., Green M., Thomas C.R., et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001, 91:2010-2015.
13. Magois E., Guigay J., Blancard P.S., Margery J., Milleron B., Lher P., et al. Multimodal treatment of thymic carcinoma: report of nine cases. Lung Cancer 2008, 59:126-132.
14. Lemma G., Loehrer P., Lee J., Langer C., Tester W., Johnson D. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. Am Soc Clin Oncol 2008, 26.
15. Igawa S., Murakami H., Takahashi T., Nakamura Y., Tsuya A., Naito T., et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2009.
16. Komatsu Y., Koizumi T., Tanabe T., Hatayama O., Yasuo M., Okada M., et al. Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma-three cases. Anticancer Res 2006, 26:4851-4855.
17. Pedersini R., Vattemi E., Lusso M.R., Mazzoleni G., Ebner H., Graiff C. Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report. Tumori 2008, 94:849-852.
18. Kurup A., Burns M., Dropcho S. Phase II study of Gefitinib treatment in advanced thymic malignancies. Am Soc Clin Oncol 2005, 23:7068. (abstract).
19. Hsu C.H., Yeh K.H., Cheng A.L. Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. Anticancer Res 1997, 17:1331-1334.
20. Oberg K., Kvols L., Caplin M., Delle Fave G., de Herder W., Rindi G., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15:966-973.
21. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004, 350:2625-2626.
22. Strobel P., Bargou R., Wolff A., Spitzer D., Manegold C., Dimitrakopoulou-Strauss A., et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010, 103:196-200.
23. Kanda S., Koizumi T., Komatsu Y., Yoshikawa S., Okada M., Hatayama O., et al. Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases. Anticancer Res 2007, 27:3005-3008.
24. Loehrer P., Yiannoutsos C., Dropcho S. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Am Soc Clin Oncol 2006, 24:7079. (abstract).
25. Oguri T., Achiwa H., Kato D., Maeda H., Niimi T., Sato S., et al. Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 2004, 50:279-282.
26. Igawa S., Murakami H., Yamamoto N. Thymic small cell carcinoma shows marked response to amrubicin. J Thorac Oncol 2009, 4:778.
27. Koizumi T., Agatsuma T., Ichiyama T., Yokoyama T., Ushiki A., Komatsu Y., et al. Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases. Med Oncol 2009.
28. Ono A., Naito T., Yamamoto N. S-1 treatment for chemorefractory thymic carcinoma. J Thorac Oncol 2008, 3:1076.
29. Zheng Z., Li X., Schell M.J., Chen T., Boulware D., Robinson L., et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008, 112:2765-2773.
30. Yasumatsu R., Nakashima T., Uryu H., Ayada T., Wakasaki T., Kogo R., et al. Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy 2009, 55:36-41.
31. Boku N., Chin K., Hosokawa K., Ohtsu A., Tajiri H., Yoshida S., et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998, 4:1469-1474.
32. Gosens M.J., Moerland E., Lemmens V.P., Rutten H.T., Tan-Go I., van den Brule A.J. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 2008, 123:1941-1949.
33. Obara S., Yamamoto K., Hosogai N., Yoshimura Y. Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma. Oral Oncol 2005, 41:276-282.
34. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
35. Harada K., Kawaguchi S., Supriatno, Kawashima Y., Yoshida H., Sato M. S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett 2005, 226:161-168.